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cation. Although the RSP appears to be effective in terms of 
harm reduction in in-patients with SUD, more cost- and 
time-efficient programs might also be suitable for this popu-
lation.  © 2016 S. Karger AG, Basel 
 Introduction 
 Smoking is believed to be the single most important 
preventable cause of death in the industrialized world, 
and it accounts for a large proportion of cancer-related, 
cardiovascular and respiratory deaths  [1–3] .
 The association between smoking and mental disor-
ders is well established, and the prevalence of smoking in 
people with mental illness is 2–4 times higher than in the 
general population  [4–6] . Patients with schizophrenia or 
substance-related disorders tend to be heavy smokers  [6] , 
and up to 80% of the clinical population of alcohol-de-
pendent people smoke  [7] . Smokers with a mental illness 
show higher levels of any dependence  [6] , more psychiat-
ric symptoms and psychiatric hospitalization and poorer 
treatment outcome than non-smoking patients  [8, 9] .
 The guidelines of both the American Psychiatric As-
sociation and the European Psychiatric Association rec-
ommend the treatment of tobacco dependence in people 
with mental illness  [10, 11] . Unfortunately, interventions 
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 Abstract 
 Aims: The present study investigated the feasibility, accep-
tance and efficacy of a newly developed cognitive behav-
ioral program for smoking cessation/reduction (‘Rethink 
your Smoking’ program, RSP) in inpatients with substance 
use disorder (SUD).  Method: One hundred ninety-nine inpa-
tients with SUD were randomly assigned to either the RSP 
(n = 101) or a minimal intervention (MI) program (n = 98). In 
addition, participants were offered optional nicotine re-
placement therapy. Data from a group of patients with SUD 
without any intervention (control group, n = 78) were includ-
ed in the analyses for comparison. Assessments were per-
formed at admission, discharge and follow-up after 3 and 
6 months.  Results: RSP proved to be feasible and was well 
accepted by participants. Patients in both interventions 
showed lower scores for physical nicotine dependence and 
number of cigarettes smoked per day and higher scores for 
various motivational parameters at discharge and 3 months 
later. Both interventions were superior to no intervention, 
but no differences were found between the RSP and MI.  Con-
clusion: A smoking cessation/reduction program is feasible 
for substance-dependent in-patients undergoing detoxifi-
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designed especially for patients with substance use disor-
der (SUD) are rare, probably because of the widespread 
beliefs among clinicians that these patients are unable or 
unwilling to quit or that smoking cessation is of second-
ary importance. However, contrary to common objec-
tions, the motivation to quit among patients with SUD 
has been shown to be comparable to that in the general 
population  [12–14] , and Mueller et al.  [15] showed that 
even during detoxification alcohol-dependent smokers 
show interest in smoking interventions. Also, findings 
implicate that mental health recovery is not jeopardized 
by smoking reduction or cessation  [14] . In fact, sobriety 
from other addictions seems to be rather improved by 
nicotine withdrawal, and participation in smoking cessa-
tion programs is recommended during treatment of the 
primary addiction  [5, 16, 17] . This opinion is supported 
by a larger body of literature, although some studies are 
contradictory  [18, 19] .
 The aforementioned guidelines for smoking cessation 
 [10, 11] recommend that interventions in tobacco-de-
pendent patients with a mental illness combine psycho-
therapeutic techniques and supportive medication (e.g., 
nicotine replacement therapy, NRT). The effectiveness of 
such programs is widely believed to increase with the in-
tensity (i.e., duration and frequency) of the treatment 
 [11] , and cognitive behavioral interventions may be effec-
tive, particularly in short-term smoking reduction  [15, 
16, 20] . However, there is evidence that even minimal 
counselling (e.g., physician advice) has similar effects on 
cessation rates, especially as concerns long-term absti-
nence from cigarettes  [21, 22] . In particular, in-patients 
with SUD without any interest in smoking cessation can 
be offered short interventions, such as brief advice  [23] . 
These findings indicate that smoking cessation programs 
should be tailored to the target group and that shorter and 
more cost-effective programs might be an appropriate 
option for in-patients with SUD.
 In the present study, we compared a cognitive behav-
ioral intervention for smoking cessation (‘Rethink your 
Smoking’ program, RSP) with a minimal intervention 
(MI) in inpatients with SUD. Patients in both interven-
tion groups were offered supplementary NRT. We evalu-
ated both the feasibility and acceptance of the interven-
tions as well as their effects on several variables. Assess-
ments were performed after 2 weeks and 3 and 6 months. 
Data from another sample of patients without any inter-
vention were used for additional comparisons. We hy-
pothesized that the cognitive behavioral intervention 
program would be feasible and well accepted by both pa-
tients and course instructors. Although both interven-
tions were expected to have positive effects on patients’ 
smoking behavior, we expected the more complex inter-
vention to have superior short-term effects.
 Methods 
 Study Design 
 This prospective, quasi-randomized, controlled study was con-
ducted from 2010 to 2012 at the Department of Psychiatry and 
Psychotherapy, Ludwig Maximilian University, Munich, to com-
pare a newly developed cognitive behavioral program for in-pa-
tients with SUD, the RSP, with a MI. The study was approved by 
the Ethics Committee of Ludwig Maximilian University, Munich, 
and all participants provided written informed consent.
 At the beginning of the detoxification and withdrawal treat-
ment, patients who agreed to participate in the study were random-
ized to the RSP or MI group according to the time of their admis-
sion to hospital. Patients admitted in the first 3 months of the study 
were allocated to RSP; those admitted in the next 3 months, to MI; 
those admitted in the next 3 months, to RSP; and so on. In the RSP 
group, patients interested in smoking cessation were invited to an 
additional individual session and to receive NRT (Nicorette ® TX 
patch, gum and lozenge) for the duration of their hospital stay. 
NRT was offered only to patients who attended the individual ses-
sion. In the MI group, participants were not offered individual ses-
sions, but were offered NRT. In case of readmission to hospital 
during the study period, patients participated again in the group 
programs, but not in the study. All patients completed an assess-
ment at baseline (t0) and discharge (t1). Both intervention groups 
were assessed by a telephone interview 3 (t2) and 6 months (t3) 
after discharge. All interventions were conducted by trained course 
instructors (1 psychologist and 2 medical students). To evaluate the 
feasibility and acceptance of the RSP, participants and course in-
structors completed questionnaires after every session (group and 
individual). The study was conducted on an open ward specialized 
in SUDs (legal and illegal substances). The main treatment offered 
is qualified detoxification, which includes cognitive behavioral 
therapy that focuses on motivation to stay abstinent. The average 
time spent in hospital is 2 weeks. Smoking at the hospital was gen-
erally only allowed outdoors, that is, on the hospital grounds.
 Before the beginning of the study, different patients on the 
same ward had completed a similar questionnaire at baseline (t0) 
and discharge (t1). These patients received no intervention for 
their tobacco dependence and were used as a no-intervention con-
trol group (CG).
 Participants 
 A total of 199 participants were recruited from the population 
of in-patients receiving withdrawal therapy for SUD at the Depart-
ment of Psychiatry and Psychotherapy. Patients were eligible to 
participate if they were aged 18 years or older, had a diagnosis of 
SUD according to ICD-10 criteria  [24] and were tobacco smokers 
with a score  ≥ 1 on the Fagerström Test of Nicotine Dependence 
(FTND)  [25, 26] . The only exclusion criterion was previous par-
ticipation in the program. Participants were not required to want 
to quit smoking. Attendance at the different group sessions (RSP 
or MI) was mandatory for all patients on the SUD ward, but par-




















   
   
   
   
   
   
   
   
   
   
   



























 ‘Rethink your Smoking’ Program 
 The RSP is a cognitive behavioral program based on an evi-
dence-based smoking cessation program ‘Das Rauchfrei-Pro-
gramm (Kompaktversion)’ (‘the smoking cessation program 
[compact version]’), which was designed and evaluated by the 
IFT (Institut für Therapieforschung)  [27] and is aimed at in-pa-
tients with SUD who are undergoing detoxification. It consists of 
one 60-minute group session a week for 2 weeks, and patients can 
begin the intervention at any time. Participants who are inter-
ested in smoking cessation can attend an additional individual 
counseling session, at which NRT is initiated if wished. Patients 
can receive NRT only after they have attended the individual ses-
sion. The intervention is based on a manual;  table 1 for a brief 
overview.
 Minimal Intervention 
 The MI in the study was a group session of about 15 min that 
briefly addressed the risks of smoking and the possible advantages 
of successful smoking cessation on abstinence from other addic-
tions. The instructors gave advice on stopping smoking and dis-
cussed the possibility of receiving free NRT during the hospital 
stay. After the group session, interested patients were given brief 
advice about the appropriate type of NRT.
 Assessments 
 At admission (t0), various self-report data were collected, in-
cluding demographic characteristics (age, sex, years of education, 
marital status), comorbid diagnoses and tobacco use history (years 
of smoking, attempts to quit). Furthermore, the questionnaire in-
cluded additional items that were recorded also at discharge (t1), 
and the 3- (t2) and 6-month (t3) follow-ups: the FTND  [25, 26] , 
number of cigarettes per day and motivation to quit. Motivation 
to quit was measured by single items concerning the motivation to 
change smoking behavior (change of behavior, ‘Wie motiviert sind 
Sie aktuell, Ihr Rauchverhalten zu verändern?’ [‘How motivated 
are you currently to change your smoking behavior?’], Likert scale 
from 1 to 5), how much participants wanted to quit smoking 
(want, ‘Wie gerne wollen Sie Nichtraucher werden/bleiben?’ 
[‘How much do you want to become/remain a non-smoker?’], Lik-
ert scale from 1 to 4) and how likely they were to do so (likely, ‘Wie 
wahrscheinlich ist es, dass Sie als Nichtraucher die Klinik verlassen 
warden?’ [‘How likely is it that you leave hospital as a non-smok-
er?’], Likert scale from 1 to 4)  [28] , with higher scores indicating 
higher levels of motivation. In the individual session, carbon mon-
oxide (CO) levels in expired air were measured by a Bedfont 
Smokerlyzer to verify participants’ information about smoking. 
Reasons for drop-out were not recorded.
 Program feasibility was rated by the instructors after every ses-
sion on a scale of 1 (low) to 5 (high; ‘Die Inhalte waren in der 
vorgegebenen Zeit gut umsetzbar’ [‘the content could be easily im-
plemented in the allowed time’]). Patient acceptance was rated by 
patients at discharge on a scale of 1 (very good) to 6 (unsatisfac-
tory; ‘Wie zufrieden sind Sie insgesamt mit dem Rauchfreipro-
gramm?’ [‘How happy are you overall with the smoking cessation 
program?’]).
 In the no-intervention CG, assessments were conducted only 
at baseline (t0) and discharge (t1). Only a limited data set is avail-
able from these 2 assessments that includes age, sex, smoking sta-
tus, length of regular tobacco consumption, number of cigarettes 
per day and the items change of behavior, want and likely. The 
FTND was not assessed.
 Data Analysis 
 Nominal data (drop-outs, demographics) were compared by 
chi-square tests; and continuous data, by one-way analyses of vari-
ance (ANOVAs). Within-group variables were compared with re-
peated measurement ANOVAs. All tests of significance used an 
alpha level of 0.05 and were reported as 2-tailed. An effect size of 
η 2  = 0.14 indicates a strong effect; η 2  = 0.06, a medium effect; and 
η 2  = 0.01, a weak effect  [29] . Statistical analyses were performed 
with the software SPSS version 23.0 for Windows.
 Results 
 Participants 
 A total of 204 patients were screened and showed in-
terest in the study, and 199 patients met inclusion criteria 
and received treatment; 5 patients were excluded due to 
former participation in the program; 101 patients were 
randomized to the RSP group and 98 to the MI group. All 
participants in the RSP group attended both group ses-
sions, and 31 (30.7%) attended an individual session. The 
post-treatment assessment was completed by 157 partici-
Table 1.  Overview of the RSP
Procedure Aim Content
Group sessions – Length: 2 weeks 
– One 60-minute group session every 
week
Psychoeducation; establish 
ambivalence about smoking and 
motivation
– 1st session: smoking, smoke-free 
life, reasons for smoking




– One 20-minute session 
– Requirement: documentation of 
number of cigarettes smoked in last 
3 days
Preparation and stabilization of 
smoking reduction or cessation
– Overview of smoking profile, CO 
assessment, and goal setting
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pants (78.9%); the 3-month follow-up, by 119 (59.8%); 
and the 6-month follow-up, by 91 (45.7%;  fig. 1 ).
 The mean age of the sample was 41.7 years (SD 10.7), 
and neither demographic variables nor any pretreatment 
variables differed between conditions (ts (197) <1.69, ps > 
0.092). Only the item change of behavior showed a statis-
tically significant difference (t (197) = 3.40, p = 0.001) in 
favor of higher motivation in the MI group.  Table 2 shows 
all demographic variables. Patients in the RSP group who 
attended an individual session showed significantly high-
er motivation (i.e., higher scores for change of behavior, 
likely and want) than patients who did not attend an in-
dividual session (ts (197) >44.92, ps < 0.001).
 Drop-out rates increased during the study but did not 
differ significantly between the 2 intervention groups. Pa-
tients with missing data at an assessment were considered 
drop-outs for this assessment. A total of 157 (78.9%) pa-
tients completed the first 2 assessments, and 64 (32.2%) 
completed all 4 assessments ( fig. 1 ; for participant flow). 
Chi-square and t tests between participants who complet-
ed all assessments and those who dropped out at any time 
showed differences in ‘primary SUD’ but not in any other 
demographic or clinical variables. Participants with mul-
tiple SUDs dropped out significantly more often than 
participants with a single SUD (χ 2 (3) = 10.20, p = 0.017).
 A limited set of clinical data were available for the CG. 
Nevertheless, we assumed that the demographic variables 
were comparable to those in the intervention groups, be-
cause all patients were in-patients on the same ward. 
Number of cigarettes per day and length of regular to-
bacco consumption did not differ between conditions (Fs 
<1.15, ps > 0.450), but change of behavior (F (2, 276) = 
7.73, p = 0.001) and likely (F (2, 276) = 3.71, p = 0.026) 
were significantly lower in the CG.
 Feasibility and Acceptance 
 The average feasibility rating of RSP for session 1 was 
4.83 (SD 0.39, n = 12); for session 2, 4.42 (SD 1.00, n = 12); 
and for the individual session, 4.06 (SD 1.15, n = 31). The 
mean patient acceptance score was 2.35 (SD 1.38, n = 80).
Signed informed consent (n = 204)
MI group (n = 98)RSP group (n = 101)
- Individual session
 (n = 31)
- Group sessions only
 (n = 70)
Follow-up t2 (n = 58)
Baseline measurement (n = 199)







Did not meet inclusion
criteria (n = 5)
Follow-up t3 (n = 45) Follow-up t3 (n = 46)
No-treatment control 
group baseline 
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 Treatment Outcomes 
 Short-Term Outcome 
 At t1, data from 157 participants were available for 
analysis. Five (6.6%) participants in the MI group and 8 
(10%) in the RSP group had stopped smoking. No differ-
ence was found between the (intervention) groups re-
garding stopping smoking (χ 2 (1) = 0.60, p = 0.440). In the 
RSP group, 5 of the 8 participants who had stopped smok-
ing had received NRT; and in the MI group, 2 of the 5 
patients.
 There was a statistically significant reduction over 
time in the FTND score (F (1, 62) = 26.98, p = 0.000, par-
tial η 2  = 0.15) and the number of cigarettes smoked per 
day (F (1, 62) = 30.49, p = 0.000, partial η 2  = 0.16) and an 
increase in the likelihood of becoming a non-smoker 
(‘likely’, F (1, 155) = 11.46, p = 0.001, partial η 2  = 0.07). 
No effects of group or interaction were found for any of 
these variables. Scores for motivation to change smoking 
behavior (change of behavior) were significantly higher 
in the MI group than in the RSP group (F (1, 155) = 8.33, 
Table 2.  Sociodemographic variables of the sample
RSP (n = 101) MI (n = 98) Total (n = 199) No-intervention 
CG (n = 72)
Age, years
Mean ± SD 41.65±10.53 41.69±10.87 41.67±10.64 40.04±10.51
Range 18–71 21–67 18–71 21–60
Sex, n (%)
Male 71 (70.3) 54 (55.1) 125 (62.8) 56 (74.7)
Female 30 (29.7) 44 (44.9) 74 (37.2) 16 (21.3)
General education, years, n (%)
0–7 9 (9.0) 5 (5.1) 14 (7.0)
8–9 42 (41.6) 35 (35.7) 77 (38.7)
10–11 23 (22.8) 36 (36.7) 59 (29.6)
12–13 27 (26.7) 21 (21.4) 48 (24.1)
Missing 0 1 (1.0) 1 (0.5)
Primary SUD, n (%)
Alcohol dependence 62 (61.4) 49 (50.0) 111 (55.8)
Multiple SUD 30 (29.7) 36 (36.7) 66 (33.2)
Prescription drug abuse 6 (5.9) 5 (5.1) 11 (5.5)
Other 3 (3.0) 0 (8.2) 11 (5.5)
Comorbid diagnoses, n (%)
Affective disorders 44 (43.6) 32 (32.7) 76 (38.2)
Neurotic, stress and somatoform disorders 4 (4.0) 8 (8.2) 12 (6.0)
Schizophrenia, schizotypal and delusional disorder 8 (7.9) 2 (2.0) 10 (5.0)
Other 2 (2.0) 7 (7.1) 9 (4.5)
No other 43 (42.6) 59 (50.0) 92 (46.2)
FTND, mean ± SD 5.81±2.24 5.47±2.60 5.65±2.42
Number of cigarettes per day, mean ± SD 23.99±11.4 23.63±12.87 23.81±12.13 24.35±13.11
Length of regular tobacco consumption
Mean ± SD 23.44±9.42 22.88±10.06 23.16±9.72 22.69±10.54
Range, years 4–53 5–52 4–53 6–45
Number of cessation attempts
Mean ± SD 2.36±4.67 2.00±3.08 2.18±3.96
Range 0–30 0–20 0–30
NRT, n (%)
During hospital stay (t1) 23 (28.0) 36 (47.4) 59 (37.6)
3-Month follow-up (t2) 2 (3.3) 2 (3.5) 4 (3.4)
6-Month follow-up (t3) 2 (4.4) 1 (2.2) 3 (3.3)
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p = 0.004, partial η 2  = 0.05), but we found no main effect 
of time and no interaction ( table 3 ;  fig. 2 ).
 In the CG, nobody stopped smoking. When the CG was 
included in the analyses, a statistically significant differ-
ence between the CG and the other 2 groups regarding 
stopping smoking was found at t1 (χ 2 (2)  = 7.752, p  = 
0.021). In all 3 groups, the number of cigarettes smoked per 
day decreased significantly over time (F (1, 228) = 17.70, 
p = 0.000, partial η 2  = 0.07). An interaction between time 
and group (F (2, 228) = 17.70, p = 0.000, partial η 2  = 0.07) 
showed that patients in the CG reduced the number of cig-
arettes smoked per day less than patients in the interven-
tion groups. The likelihood to become a non-smoker (like-
ly) increased significantly over time (F (1, 228) = 8.34, p = 
0.004, partial η 2  = 0.04) and differed significantly between 
groups (F (2, 228) = 8.00, p = 0.000, partial η 2  = 0.07).
 Long-Term Outcome 
 At the 3-month follow-up, only 1 participant in the MI 
group and none in the RSP group was abstinent from cig-
arettes, and there was no statistically significant associa-
tion between group and smoking cessation (χ 2 (2) = 0.97, 
p = 0.616). However, over time there was a statistically 
significant reduction in the FTND score (F (3, 183)  = 
16.18, p = 0.000, partial η 2  = 0.21) and the number of cig-
arettes smoked per day (F (3, 183) = 18.58, p = 0.000, par-
tial η 2  = 0.23) and an increase in the willingness to stop 
smoking (want, F (3, 186) = 4.10, p = 0.015, partial η 2  = 
0.06). No effects were found for motivation to change 
smoking behavior (change of behavior) or likelihood to 
become a non-smoker (likely;  fig. 2 ).
 Impact of Individual Sessions/NRT 
 A total of 23 patients in the RSP group received NRT 
(74.2% of all those who attended an individual session, 
n  = 31). The differences in motivation between RSP 
 patients who attended an individual session and those 
who did not were maintained over time. For short-term 
outcomes, we found a statistically significant interac-
tion between time and group, that is, patients who at-
tended an individual session benefitted even more from 
RSP in terms of lower scores on the FTND (F (1, 80) = 
7.45, p  = 0.008, partial η 2   = 0.09), fewer cigarettes 
smoked per day (F (1, 79) = 19.92, p = 0.000, partial η 2  = 
0.20) and increased motivation to change smoking be-
havior (change of behavior, F (1, 79) = 12.74, p = 0.001, 
partial η 2  = 0.14) than RSP patients who did not attend 
an individual session and therefore did not use NRT. 
There were no significant interaction effects in long-
term outcomes.
 In the MI group, a total of 36 patients (36.7%) decided 
to receive NRT. For short-term outcomes, we found a sta-
tistically significant interaction between time and group, 
that is, patients who received NRT showed even lower 
scores on the number of cigarettes smoked per day (F (1, 
74) = 15.55, p = 0.000, partial η 2  = 0.17) and FTND (F (1, 
73) = 4.61, p = 0.035, partial η 2  = 0.06). For long-term 
outcomes, we found statistically significant interactions 
between time and group for the motivation to change 
smoking behavior (change of behavior, F (3, 90) = 15.36, 
p = 0.000, partial η 2  = 0.34) and the likelihood to become 
a non-smoker (likely F (3, 90) = 4.26, p = 0.007, partial 
η 2   = 0.12), that is, patients who received NRT showed 
Table 3.  Repeated measures ANOVA: RSP vs. MI
Variable Main effects Interaction
time group  time × group
F p value η2 F p value η2 F p value η2
FTND (t0–t1) 26.98 0.000 0.15 1.72 0.191 0.01 3.21 0.075 0.02
FTND (t0–t3) 16.18 0.000 0.21 0.96 0.330 0.02 1.05 0.372 0.02
Cigarettes/day (t0–t1) 30.49 0.000 0.16 2.14 0.145 0.01 0.92 0.340 0.01
Cigarettes/day (t0–t3) 18.58 0.000 0.23 0.74 0.393 0.01 1.13 0.337 0.02
Change of behavior (t0–t1) 3.14 0.079 0.02 8.33 0.004 0.05 0.21 0.651 0.00
Change of behavior (t0–t3) 2.24 0.114 0.04 0.54 0.466 0.01 0.62 0.532 0.01
Likely (t0–t1) 11.46 0.001 0.07 2.05 0.155 0.01 0.04 0.842 0.00
Likely (t0–t3) 2.61 0.065 0.04 2.11 0.152 0.03 0.49 0.648 0.01
Want (t0–t1) 0.54 0.466 0.00 2.58 0.110 0.02 1.25 0.266 0.01
Want (t0–t3) 4.10 0.015 0.06 0.92 0.342 0.02 0.40 0.698 0.01




















   
   
   
   
   
   
   
   
   
   
   























Eur Addict Res 2016;22:268–276
DOI: 10.1159/000446430
274
higher motivational scores at the beginning, which de-
creased over time, while motivation in patients without 
NRT increased in terms of those 2 motivational scores 
(change of behavior and likely).
 Discussion 
 The present study investigated the feasibility, accep-
tance and efficacy of a smoking cessation program for in-
patients with SUD undergoing detoxification. This popu-
lation of patients is generally believed to be either unable 
or unwilling to stop or reduce smoking. Despite the fact 
that the program was mandatory for all patients (although 
participation in the study was optional), it was well ac-
cepted and feasible.
 In terms of efficacy, the RSP was effective, but it was 
not superior to MI. Patients of both groups showed less 
physical nicotine dependence and smoked fewer ciga-
rettes per day at discharge and at 6-month follow-up than 
at admission. Participants rated the likelihood of becom-
ing a non-smoker higher at discharge, and their willing-
ness to stop smoking was higher even after 6 months. 
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were superior to no intervention, and therefore, we con-
clude that both the RSP and MI had a significant effect on 
inpatients’ smoking behavior and that the mere hospital 
stay was not responsible for this effect. Patients’ assess-
ments of how likely they are to stay off cigarettes after they 
leave hospital have been shown to be the best predictor 
for future cessation  [28] . Thus, our study shows that such 
interventions are useful in terms of smoking reduction, 
even in the difficult-to-treat population of substance-de-
pendent in-patients undergoing detoxification. Conse-
quently, we recommend that at least MI should be applied 
by default.
 This study also showed that additional individual ses-
sions and NRT had only short-term effects on physical 
nicotine dependence, number of cigarettes smoked per 
day and motivation to change smoking behavior for the 
participants in the RSP group. We found no long-term 
differences in smoking reduction and dependence be-
tween patients who received additional counseling and 
NRT and those who did not. In the MI group, we found 
short-term effects on physical nicotine dependence and 
number of cigarettes smoked per day, but not on motiva-
tional variables. In the long term, the use of NRT during 
the hospital stay did not affect smoking reduction and 
dependence, but it did decrease motivation to change 
smoking behavior and the likelihood to become a non-
smoker. Because ongoing NRT is generally associated 
with better smoking cessation outcomes  [10] , these find-
ings might be due to the fact that NRT was not as easily 
available after discharge.
 The study had several strengths. The RSP was highly 
structured and based on an extensive manual, and course 
instructors and ward staff were trained in advance. The 
study participants of the 2 intervention groups were 
comparable regarding demographic and pretreatment 
variables and therefore randomization was successful. 
However, findings are limited by the high drop-out rate, 
especially for the long-term comparison. High drop-out 
rates are not uncommon among substance-dependent 
patients  [30] , and a detailed analysis of reasons for drop-
out might provide additional information about the ef-
ficacy of intervention programs. Furthermore, the as-
signment to RSP or MI on the basis of the 3-month pe-
riod in which a patient was admitted to hospital holds the 
risk of systematic biases such as seasonal effects, staff 
changes and a changing institutional attitude toward 
smoking cessation. Another limitation is the lack of a no-
intervention CG with a full set of data, including physical 
nicotine dependence and follow-up comparisons; only 
limited data were available for the CG used in our study, 
so we could make only basic comparisons. A better CG 
in future studies would allow additional conclusions to 
be drawn. Furthermore, data from all groups were based 
on self-report, which are vulnerable to bias, and bio-
chemical verification (measurement of CO) was only 
conducted during individual sessions. Lastly, patients’ 
reasons for participating in the study were not assessed. 
Assumedly, patients who participated were already more 
motivated to rethink their smoking than patients who 
did not.
 To conclude, a smoking cessation/reduction program 
is feasible for substance-dependent in-patients undergo-
ing detoxification. The RSP was well accepted, and both 
the RSP and MI had positive effects on short-term out-
comes of physical nicotine dependence, number of ciga-
rettes smoked per day and motivation to quit smoking. It 
is to be noted that an effect on actual smoking cessation 
could not be found. However, while there is no clear evi-
dence that smoking reduction decreases the risks of 
smoking-related diseases, smoking reduction is associ-
ated with a higher probability of future cessation  [31, 32] . 
The more extensive RSP was not superior to MI. Because 
MI is more time and cost-effective, one can argue that 
such a low-intensity intervention might be preferable for 
this population. Fiore et al.  [11] found that the length of 
the cessation treatment is associated with its success, and 
Stead et al.  [33] recommend using NRT for at least 
8 weeks. Our findings also suggest that ongoing treatment 
with NRT should be provided, but that lower intensity 
cognitive therapy, that is, shorter sessions, might be suf-
ficient. We support the opinion of experts in this field, 
that is, that treatment of nicotine dependence in patients 
with comorbid SUD is important and advisable  [10, 16, 
34] . However, it should be noted that treatment should be 
maintained after discharge from hospital. Future research 
on smoking cessation for substance-dependent in-pa-
tients should take these findings into consideration. Fur-
thermore, studies should examine different subgroups of 
this population more closely and shape interventions ac-
cording to their special needs.
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